Stemedica Initiating Phase IIb/III Clinical Trial for Patients with Chronic Ischemic Stroke
StemProtein, LLC (a subsidiary of Stemedica Cell Technologies, Inc.) a leading manufacturer of physiologically balanced growth factors, exosomes, and tissue-restoring proteins received United States Patent No. 10,973,757 entitled “Biodegradable Microneedle Device.” The patent issued on April 13, 2021.